Develops small-molecule medicines designed to break down disease-causing proteins for cancer and inflammatory and neurological diseases.
10-K for FY2025, filed Feb 26, 2026We are a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation, or TPD, science…View ↗
Our clinical pipeline has two oncology degraders, cemsidomide, an IKZF1 and IKZF3 degrader, for multiple myeloma, or MM, and CFT8919, an…View ↗
We are further diversifying our internal pipeline by developing new degraders focused on inflammation, neuroinflammation, and…View ↗
C4T earns revenue from research collaborations and licenses through upfront fees, cost reimbursements, option and milestone payments, and royalties on licensed-product sales. Collaboration revenue is earned over the agreement's work period, while a distinct upfront license fee is earned when the partner can use the rights.
10-K for FY2025, filed Feb 26, 2026To date, we have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products for the…View ↗
The Company enters into collaboration and licensing agreements with strategic partners, which are within the scope of ASC 606, under which…View ↗
If the license to the Company’s intellectual property is determined to be distinct from the other promises or performance obligations…View ↗
$35.9M
10-K for FY2025, filed Feb 26, 2026
$35.9M ↗
Collaborators such as Merck KGaA and Roche work with the company on drug discovery; Betta Pharma licenses and develops CFT8919 in Greater China.
10-K for FY2025, filed Feb 26, 2026
No. It lost $105M in FY2025.
10-Q for Q3 FY2026, filed Nov 5, 2026
−$21.8MView ↗
8-K, filed Apr 9, 2026
On April 8, 2026, C4 Therapeutics, Inc. (“C4T”) entered into a Research Collaboration and License Agreement (the “License Agreement”) with…View ↗
Shrinking. Revenue fell 21% in 4 years, from $45.8M in FY2021 to $35.9M in FY2025, about 6% a year.
Pipeline focus
The older report listed oncology candidates for multiple myeloma and lymphoma, synovial sarcoma, BRAF-mutant tumors, and EGFR-mutant lung cancer. The latest report centers the clinical pipeline on multiple myeloma and EGFR-mutant lung cancer while describing discovery work in inflammation, neuroinflammation, and neurodegeneration.
10-K for FY2022, filed Feb 23, 2023 10-K for FY2025, filed Feb 26, 2026Our most advanced product candidate, CFT7455, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3…View ↗
Our next most advanced product candidate, CFT8634, is an orally bioavailable BiDAC degrader of a protein target called BRD9, currently in…View ↗
We are also developing CFT1946, an orally bioavailable BiDAC degrader specifically to be potent and selective against BRAF V600 mutant…View ↗
Additionally, we are developing CFT8919, an orally bioavailable, allosteric, mutant-selective BiDAC degrader of epidermal growth factor…View ↗
Loading...